Delpharm has partnered with the Government of Canada to upgrade its injectable manufacturing site in Boucherville, Quebec.
The company’s latest move ensures the facility remains operational within Canada, securing the domestic supply chain for sterile injectable medications.
The Boucherville plant currently manufactures 20 out of the 100 essential medicines critical to the Canadian healthcare system, making it a significant contributor to the supply of generic products necessary for surgeries and intensive care nationwide.
A decade-long agreement has been signed between Delpharm and Sandoz, providing a stable framework to guarantee a reliable supply of vital medicines to Canadians.
This initiative aims to enhance the country’s healthcare self-sufficiency amid ongoing global supply chain issues.
The modernisation project represents an investment exceeding C$200m and will ensure the retention of over 500 skilled positions in Quebec.
Scheduled to continue until 2031, the plan includes expanding the facility, installing a new advanced filling line, and upgrading existing equipment in compliance with updated Health Canada standards. As part of this initiative, 95% of the equipment will be replaced.
Canada’s Minister of Innovation, Science and Industry Anita Anand said: “This significant investment is a key step in securing Canada’s industrial biomanufacturing footprint and strengthening our resilience against future health emergencies and supply chain disruptions.
“By increasing our domestic capacity to produce essential sterile injectables, we are ensuring that Canadians are best positioned to have access to the medicines they need.”
Delpharm site director Mathieu Grondin said: “The injectable medications we produce at the site for Sandoz are necessary for almost all surgeries performed in Canada and used to treat patients in intensive care units.
“This reality makes the Sandoz-Delpharm partnership an essential component for the proper functioning of the country’s healthcare system.”
